



National Psoriasis Foundation

How we are using Dimensions

Michael Siegel, PhD
Vice President of Research Programs

September 17, 2017

NPF Research Programs


NPF Mission

To drive efforts to cure psoriatic disease and improve the lives of those affected.

Research Programs Objective

Strengthen and support research towards our mission.

Approach



NPF Research Activities



NPF Annual Survey




citizen scientist
You're the subject and the scientist

**Psoriatic Disease
Research Ambassadors**

**Medical Board
Niche Papers**




Clinical Trials Support



Grants and Fellowships

Discovery Grants	Translational Research Grants	Psoriatic Disease Research Fellowships
------------------	-------------------------------	--

Meetings



NPF Research Staff

Left for another job

Lindsey Shankle, MPH

- **Patient-Centered Research Manager**

Moved to Seattle

Mike Siegel, PhD

- **Vice President of Research Programs**

Use of Dimensions #1



- **Ammunition to support current partners**
- **Identification and recruitment of potential new partners**
 - Organizations
 - Individuals

Use of Dimensions #2

Grants and Fellowships

Discovery Grants	Translational Research Grants	Psoriatic Disease Research Fellowships	Bridge Grants
PsA Research Grant*	Challenge Grants	Early Career Research Grants	NIH-NPF Fellowship in Translational Medicine

- Identify potential applicants
- Identify potential reviewers
- Identify trends to help refine programs
- Program analysis

The screenshot shows the 'Edit grant application' interface in the Dimensions software. The top navigation bar includes 'Discover', 'Categorize', 'Analyze', and 'Workflow'. The main form contains the following fields:

- Workspace: - No workspace assigned -
- Grant application ID: [Empty field]
- Date submitted (DD/MM/YYYY): [Empty field]
- Date awarded (DD/MM/YYYY): [Empty field]
- Funding start date (DD/MM/YYYY): [Empty field]
- Funding end date (DD/MM/YYYY): [Empty field]
- Title: Metabolomics Profiling for Identification of Potential Biomarkers for Atherosclerosis Progression in Psoriatic Disease
- Applicant first name: Lili
- Applicant middle name: [Empty field]
- Applicant surname: Eder
- Organization name: University of Toronto, Toronto, Canada
- Role: PI
- Abstract: Psoriasis and psoriatic arthritis (PsA) are associated with increased cardiovascular morbidity that is independent of established cardiovascular risk factors. Little is known about the underlying mechanisms of atherogenesis in patients with psoriatic disease. Current guidelines recognize the need for cardiovascular risk stratification in psoriatic patients. However, clinical risk prediction algorithms, such as the Framingham risk score, underestimate cardiovascular risk in these patients. Identification of laboratory biomarkers that improve cardiovascular risk stratification is highly desirable as it may optimize primary prevention of cardiovascular events in psoriatic patients. Given the metabolic nature of atherosclerosis, circulating metabolites represent a source of potential biomarkers to augment risk prediction. Novel technologies for high-throughput profiling of metabolite status, termed metabolomics, can
- Specific aims: [Empty text area]

On the right side, there is a 'Concept Panel' with a list of concepts and checkboxes:

- atherosclerosis progression
- cardiovascular risk
- metabolite
- atherosclerosis
- cardiovascular risk factor
- metabolomic profiling
- metabolic status
- patient
- predictive model
- potential biomarkers
- cardiovascular event
- PSA
- psoriasis
- Framingham Risk Score
- predictive algorithm

Buttons for 'Delete', 'Save', and 'Cancel' are located at the top right of the form area.

Use of Dimensions #3



- Solicit manuscripts
- Identify potential reviewers
- Build editorial board

Discover | Categorize | Analyze | Workflow | Contact | Support | msiegel@psoriasis.org

Keyword search | Abstract search | Save as favorite

Q psoriasis and depression x

Projects | Funders | Researchers | Organizations | Places | Categories

Results | Visualizations

Sort by: Aggregated Funding Amount

Name	Organization, Country	Funded From - Through	Projects	Funding Amount Aggregated
<input type="checkbox"/>	Mark E Gurney deCODE Genetics (Iceland), Iceland	2011 - 2019	1	USD 4.0 M
<input type="checkbox"/>	Jan A Moynihan University of Rochester, United States	1989 - 2021	1	USD 2.4 M
<input type="checkbox"/>	Anne M Bowcock Imperial College London, United Kingdom	1978 - 2017	1	USD 998 K
<input type="checkbox"/>	Weixiong Zhang Washington University in St. Louis, United States	2009 - 2017	1	USD 998 K
<input type="checkbox"/>	Martin Stacey University of Leeds, United Kingdom	2010 - 2018	1	USD 652 K
<input type="checkbox"/>	Miriam Wittmann University of Leeds, United Kingdom	2015 - 2018	1	USD 652 K
<input type="checkbox"/>	Philip Helliwell University of Leeds, United Kingdom	2015 - 2018	1	USD 652 K
<input type="checkbox"/>	Dennis McGonagle University of Leeds, United Kingdom	2012 - 2018	1	USD 652 K
<input type="checkbox"/>	Charles S Hoffman	1991 - 2009	1	USD 427 K

Questions?